Clearance of increased serum advanced glycosylation end products in patients with end stage renal disease by hemodialysis.
OBJECTIVE
To study the effect of removal of hemodialysis using acetate membrane on serum advanced glycosylation end products (AGEP) in 36 patients (59.1 +/- 1.6) with end stage renal disease (ESRD).


METHODS
Serum AGEP levels were determined with quantitative fluorescence spectrometry, flow injection analysis (FIA), and competitive enzyme-linked immunosorbent assay (ELISA) using a polyclonal antibody directed against AGEP.


RESULTS
The serum AGEP levels in patients with ESRD quantified by fluorescence spectrometry, FIA, and ELISA were higher than those in controls [(25 +/- 5) vs (7.5 +/- 1.5), (6.1 +/- 1.8) vs (1.4 +/- 0.5), and (37 +/- 20) vs (9 +/- 10) kU/L, respectively] and markedly reduced to [(22 +/- 6), (4.2 +/- 1.4), and (19 +/- 14) kU/L, respectively] after hemodialysis.


CONCLUSIONS
Increased serum AGEP levels in the circulation of patients with ESRD were reduced effectively by hemodialysis.
Liu
N F
NF
Department of Cardiology, First Affiliated Hospital, Nanjing Railway Medical College, Nanjing 210009, China. nfliu@public1.ptt.js.cn
Sun
Z L
ZL
Liu
B C
BC
D000368:Aged; D002908:Chronic Disease; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D017022:Flow Injection Analysis; D005921:Glomerulonephritis / Q000150:complications; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000209:etiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009395:Nephritis, Interstitial / Q000150:complications; D006435:Renal Dialysis; D013050:Spectrometry, Fluorescence
D017127:Glycation End Products, Advanced